FFO
HLVX

Fortitude Family Office’s HilleVax HLVX Stock Holding History

Fortitude Family Office’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-385
Closed -$678 – 1332
2024
Q3 		$678 Buy
+385
New +$987 ﹤0.01% 1139

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Fortitude Family Office's HLVX Position: Q4 2024 in Review

Fortitude Family Office sold out of HilleVax (HLVX) in Q4 2024, closing a stake of 385 shares — an estimated $678 sold.

Fortitude Family Office first reported a position in HLVX in Q3 2024 and held it in 1 quarter. The position peaked at $678 in Q3 2024. 76 funds tracked by Wall St. Rank hold HLVX as of Q4 2024.

  • Fortitude Family Office reported no remaining HilleVax position as of Q4 2024 after selling out during the quarter.
  • Fortitude Family Office sold 385 HilleVax shares in Q4 2024, an estimated $678.
  • Fortitude Family Office first reported a position in HilleVax in Q3 2024 and held it in 1 quarter.
  • Fortitude Family Office's HilleVax position peaked at $678 in Q3 2024.
  • 76 funds tracked by Wall St. Rank held HilleVax as of Q4 2024.

Based on Fortitude Family Office's 13F filing for Q4 2024, filed 10 Jan 2025.